The indication was expanded to include R/R del(17p) or mutated-TP53 CLL based on the RESONATE-17 trial [84,85], demonstrating a high ORR (64%) and 24-months PFS (63%) in 144 patients with R/R del(17p) CLL. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.